Methods: Patients having an identifiable cause of peripheral neuropathy, except alcohol, were excluded from the study. Patients with evidence of vitamin B 12 deficiency or diabetes were also ...
Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...
Some diseases producing liver dysfunction can independently cause peripheral neuropathy ... was 88% compared with 56% in the non-alcohol group. The mean neuropathy score was 3 ± 0.44 in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback